Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
Neither atezolizumab plus chemotherapy nor atezolizumab alone improved overall survival when compared to chemotherapy alone in patients with advanced urothelial cancer in the phase 3 IMvigor130 trial. Neither atezolizumab plus chemotherapy nor atezolizumab alone improved OS when compared to chemotherapy alone in patients with advanced urothelial cancer.
16.10.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines . Seite 1